Paul Kellam, a professor of virus genomics at Imperial College London, has joined Kymab Ltd to advise on the company’s work in the areas of vaccines and infectious disease. Kymab is an antibody development company. Professor Kellam is an internationally recognized expert in examining the genomes of emerging infectious diseases. Also joining the company is Igor Theurl, professor of medicine at the University of Innsbruck, Austria. He will lead the discovery of medicines for blood diseases. Finally, Matthew McCourt, former director of oncology biology at MedImmune/AstraZeneca, will manage immuno-oncology.
Kymab announced the appointments on 14 April 2016.
Copyright 2016 Evernow Publishing Ltd